Biologikatherapie in der Behandlung der atopischen Dermatitis und des Asthma bronchiale

Nora Knappe; Christian Vogelberg

doi:10.1055/a-2296-6156

Kinder- und Jugendmedizin, Table of Contents

Kinder- und Jugendmedizin 2024; 24(03): 177-184
DOI: 10.1055/a-2296-6156

Schwerpunkt

Biologikatherapie in der Behandlung der atopischen Dermatitis und des Asthma bronchiale

Welche Optionen sind für Kinder verfügbar?Biologic therapy in the treatment of atopic dermatitis and bronchial asthmaWhat options are available for children?

Nora Knappe

¹Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Kinder- und Jugendmedizin Dresden, Fachbereich Kinderpneumologie/Allergologie

,

Christian Vogelberg

¹Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Kinder- und Jugendmedizin Dresden, Fachbereich Kinderpneumologie/Allergologie

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Biologika, im engeren Sinne molekulare Antikörper, sind ein moderner Ansatz auch bei der Therapie pneumologischer und allergologischer Krankheitsbilder. Durch eine gezielte Auswahl je nach Phäno- und Endotyp, bietet sich die Möglichkeit einer individuellen Behandlung. In diesem Artikel wird insbesondere auf die Therapieoptionen der mittelschweren bis schweren atopischen Dermatitis sowie des schweren Asthma bronchiale fokussiert.

ABSTRACT

Biologics, in the narrower sense molecular antibodies, are a modern approach also in the therapy of respiratory and allergological diseases. A targeted selection depending on the phenotype and endotype offers the possibility of an individual treatment. This article focusses in particular on the treatment options for moderate to severe atopic dermatitis and severe bronchial asthma.

Schlüsselwörter

Asthma bronchiale - atopische Dermatitis - atopisches Ekzem - Neurodermitis - Biologika

Keywords

Bronchial asthma - atopic dermatitis - atopic eczema - neurodermitis - biologicals

Full Text

References

Literatur
1 Langen U, Schmitz R, Steppuhn H. Häufigkeit allergischer Erkrankungen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1) [Prevalence of allergic diseases in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56 (5–6): 698–706. German. doi: 10.1007/ s00103-012-1652-7
2 S3-Leitlinie „Atopische Dermatitis“ (AWMF-Registernr. 013–027) (2023. Im Internet:. https://register.awmf.org/de/leitlinien/detail/013-027 Stand: 05.12.2023
3 Agache I, Akdis CA, Akdis M. et al EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy 2021; 76 (04) 988-1009
4 Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 2017; 13 (05) 425-437
5 Yamanishi Y, Mogi K, Takahashi K. et al Skin-infiltrating basophils promote atopic dermatitis-like inflammation via IL-4 production in mice. Allergy 2020; 75 (10) 2613-2622
6 Weidinger S, Beck LA, Bieber T. et al Atopic dermatitis. Nat Rev Dis Primers 2018; 04 (01) 1
7 Wollenberg A, Beck LA, Blauvelt A. et al Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020; 182 (05) 1120-1135
8 Drucker AM, Morra DE, Prieto-Merino D. et al Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA Dermatol 2022; 158 (05) 523-532
9 Amano W, Nakajima S, Kunugi H. et al The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol 2015; 136 (03) 667-677.e7
10 Adtralza: EPAR – Product Information (November 2023). Im Internet. https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf Stand: 05.12.2023
11 Blauvelt A, Teixeira HD, Simpson EL. et al Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to- Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 2021; 157 (09) 1047-1055
12 Silverberg JI, Guttman-Yassky E, Thaçi D. et al Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med 2023; 388 (12) 1080-1091
13 Torrelo A, Rewerska B, Galimberti M. et al Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol 2023; 189 (01) 23-32
14 Simpson EL, Lacour JP, Spelman L. et al Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183 (02) 242-255
15 Callewaert C, Nakatsuji T, Knight R. et al IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Invest Dermatol 2020; 140 (01) 191-202.e7
16 Bagel J, Nguyen TQ, Lima H. et al Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE). Dermatol Ther (Heidelb) 2022; 12 (06) 1417-1430
17 Bosma AL, Spuls PI, Garcia-Doval I. et al TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. Br J Dermatol. 2020; 182 (06) 1423-1429
18 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma – Leitlinienreport, 4. Auflage. Version 1. 2020. DOI: 10.6101/AZQ/000470. Im Internet. www.asthma.versorgungsleitlinien.de Stand 05.12.2023
19 Agache I, Akdis CA, Akdis M. et al EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy 2021; 76 (01) 14-44
20 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Im Internet. www.ginasthma.org Stand 05.12.2023
21 Normansell R, Walker S, Milan SJ. et al Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 01: CD003559
22 Milgrom H, Berger W, Nayak A. et al Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108 (02) E36
23 Baena-Cagnani CE, Teijeiro A, Canonica GW. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr Opin Allergy Clin Immunol 2015; 15 (03) 267-271
24 Bacharier LB, Maspero JF, Katelaris CH. et al Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med 2021; 385 (24) 2230-2240
25 Castro M, Corren J, Pavord ID. et al Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 2018; 378 (26) 2486-2496
26 Bacharier LB, Maspero JF, Katelaris CH. et al Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med 2023; 12 (01) 45-54
27 Menzies-Gow A, Corren J, Bourdin A. et al Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med 2021; 384 (19) 1800-1809
28 Bagnasco D, Testino E, Nicola S. et al Specific Therapy for T2 Asthma. J Pers Med 2022; 12 (04) 593
29 Lightwood D, Tservistas M, Zehentleitner M. et al Efficacy of an Inhaled IL-13 Antibody Fragment in a Model of Chronic Asthma. Am J Respir Crit Care Med 2018; 198 (05) 610-619